in hip arthroplasty patients in terms of overall or proximal DVT rates, major bleeding events, or clinical thromboembolic events at 3 months after surgery. Even with prophylaxis, hip arthroplasty ...

these agents have the potential for becoming the agent of choice for both prophylaxing and treating deep vein thrombosis. As with any form of pharmacologic prophylaxis, the low molecular weight ...